CYP2D6 poor metabolizers had ~5-fold higher payload exposure and excess grade ≥3 mucositis, neutropenia, febrile neutropenia, ...
Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) (Actinium or the Company), a pioneer in the development of targeted ...
Now, after years of experimenting with common bean plants in the lab and in the agricultural fields of Oaxaca, Mexico, ...
A triple-targeted preclinical therapy combining daraxonrasib, afatinib, and SD36 drove durable pancreatic cancer regression ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results